RxSight, Inc. revised earnings guidance for the year 2023. For the year, the company expects revenue guidance range of $79.0 million to $84.0 million, representing implied growth of 61% to 71% compared to 2022, up from prior guidance of $78.0 million to $83.0 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
62.36 USD | -0.45% | +3.57% | +54.66% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+54.66% | 2.43B | |
-6.46% | 179B | |
+3.39% | 113B | |
-3.68% | 67.88B | |
+5.44% | 52.03B | |
+5.70% | 43.3B | |
+4.45% | 41.79B | |
+25.42% | 32.49B | |
+14.00% | 25.65B | |
-4.29% | 24.55B |
- Stock Market
- Equities
- RXST Stock
- News RxSight, Inc.
- RxSight, Inc. Revises Earnings Guidance for the Year 2023